Bell Investment Advisors Inc Sells 510 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 24th, 2023

Bell Investment Advisors Inc trimmed its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 45.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 621 shares of the company’s stock after selling 510 shares during the period. Bell Investment Advisors Inc’s holdings in Johnson & Johnson were worth $96,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Sierra Capital LLC raised its holdings in shares of Johnson & Johnson by 0.6% in the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares in the last quarter. MTM Investment Management LLC raised its stake in shares of Johnson & Johnson by 0.5% during the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after acquiring an additional 61 shares in the last quarter. Lockerman Financial Group Inc. raised its stake in shares of Johnson & Johnson by 2.4% during the 4th quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock worth $474,000 after acquiring an additional 62 shares in the last quarter. OneAscent Financial Services LLC raised its stake in shares of Johnson & Johnson by 3.3% during the 1st quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after acquiring an additional 63 shares in the last quarter. Finally, Addison Advisors LLC raised its stake in shares of Johnson & Johnson by 0.8% during the 4th quarter. Addison Advisors LLC now owns 7,862 shares of the company’s stock worth $1,389,000 after acquiring an additional 64 shares in the last quarter. 67.57% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Morgan Stanley reissued an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. Barclays boosted their target price on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Monday, July 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $171.80.

Read Our Latest Analysis on JNJ

Johnson & Johnson Stock Down 0.9 %

JNJ stock opened at $164.54 on Thursday. The firm’s fifty day simple moving average is $166.61 and its 200-day simple moving average is $161.45. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The company has a market capitalization of $427.63 billion, a P/E ratio of 33.31, a price-to-earnings-growth ratio of 2.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same period in the prior year, the firm posted $2.59 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. As a group, equities research analysts forecast that Johnson & Johnson will post 10.75 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,163 shares of company stock valued at $7,928,856. Corporate insiders own 0.20% of the company’s stock.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.